The parties are fighting over EP 1 467 728. The patent protects the combination of the angiotensin receptor blocker valsartan and the neutral endopeptidase inhibitor sacubitril. The two compounds form the basis of Novartis’ drug Entresto, us...
Subscribe to JUVE Patent’s news feed.
Click on “Follow” and decide if you want to get news from JUVE Patent via RSS, as email newsletter, via mobile or on your personal news page.
Subscription to JUVE Patent comes without risk as you can unsubscribe instantly at any time.
You can also filter the feed to your needs via topics and keywords so that you only receive the news from JUVE Patent which you are really interested in. Click on the blue “Filter” button below to get started.
Title: JUVE Patent